The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality

The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality

The purpose of this review is to analyze the results of randomized clinical trials, meta-analyses of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate on the risk of myocardial infarction in patients with atrial fibrillation. A pivotal RE-LY study on...

Full description

Bibliographic Details
Main Authors:	B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2020-05-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	dabigatran rivaroxaban apixaban myocardial infarction atrial fibrillation
Online Access:	https://www.rpcardio.online/jour/article/view/2168

Similar Items

Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01)

Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2019-11-01)

Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2019-11-01)

A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01)

Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01)

Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01)

Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions
by: V. A. Ionin, et al.
Published: (2021-05-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES
by: Ya. P. Dovgalevskiy, et al.
Published: (2016-01-01)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction
by: Z. D. Kobalava, et al.
Published: (2021-03-01)

Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
by: Tommaso Sacquegna, et al.
Published: (2015-12-01)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair
by: Amgad Mentias, et al.
Published: (2022-09-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Factors associated with inappropriate reduced doses of non-vita-min K antagonist oral anticoagulants in patients with atrial fibrillation
by: V. A. Ionin, et al.
Published: (2021-10-01)

Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation
by: M. A. Gabitova, et al.
Published: (2020-01-01)

SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A TWO-YEAR COHORT STUDY
by: A. V. Zhilenko, et al.
Published: (2017-07-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Assessment and predictors of inappropriate dose of direct oral anticoagulants
by: Mosaad O. Almegren
Published: (2024-01-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS
by: A. А. Sokolova, et al.
Published: (2017-12-01)

COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
by: V. A. Sulimov, et al.
Published: (2015-09-01)

Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective
by: Vidal Hector O, et al.
Published: (2011-07-01)

Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true
by: Yu. A. Bunin, et al.
Published: (2016-09-01)

Direct oral anticoagulants in atrial fibrillation patients aged 75 years or older: Efficacy and safety balance
by: V V Fomin, et al.
Published: (2017-04-01)

New oral anticoagulants and cardiac safety: do we have a problem?
by: E. M. Nifontov
Published: (2018-04-01)

Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
by: Jayasree Pillarisetti, et al.
Published: (2020-11-01)

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
by: Jamshed Dalal, et al.
Published: (2015-12-01)

Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
by: N. Z. Gasymova, et al.
Published: (2019-05-01)

New anticoagulant drugs versus warfarin in atrial fibrillation: economic evaluation and cost-effectiveness analysis
by: Mauro Silingardi
Published: (2013-12-01)

The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation
by: A. N. Turov, et al.
Published: (2020-03-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

Dabigatran and rivaroxaban in the patients with atrial fibrillation and venous thrombembolism: our first clinical experience
by: Alenka Mavri, et al.
Published: (2015-01-01)

Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry
by: Agnieszka Kapłon-Cieślicka, et al.
Published: (2022-05-01)

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures
by: Yasin Emre KAYA, et al.
Published: (2019-12-01)

Utilization and prescribing patterns of direct oral anticoagulants
by: Whitworth MM, et al.
Published: (2017-03-01)

Anticoagulant therapy in patients with atrial fibrillation and reduced kidney function of diabetic and non-diabetic etiologies
by: A A Sokolova, et al.
Published: (2017-12-01)

Incidence of Osteoporosis in Primary Care Patients with Atrial Fibrillation Receiving Different Oral Anticoagulants
by: Woldesellassie M. Bezabhe, et al.
Published: (2022-10-01)